Physician profile
Smitha Balachandran
NPI 1508327479
$697.27
in general payments reported to CMS, 2019-2025
12 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $355 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.40 | 2024-2025 | Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.14 | 2024-2025 | Ofev |
| Mylan Specialty L.P. | $83.38 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $49.87 | 2024-2025 | Glassia |
| Amgen INC. | $41.47 | 2024 | Tezspire |
| Glaxosmithkline, LLC. | $38.40 | 2024-2025 | Trelegy Ellipta |
| Genzyme Corporation | $36.45 | 2024 | |
| Pulmonx Corporation | $36.01 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Viatris Specialty LLC | $33.02 | 2025 | Yupelri |
| Fisher & Paykel Healthcare INC | $26.56 | 2025 | Fisher & Paykel Healthcare |
| Verona Pharma, INC. | $23.59 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $22.98 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Balachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.